David R. Wells is an operationally-minded CFO with solid instincts for “the numbers”. He possesses over 30 years of experience in finance, operations and administrative positions. While mainly focused on medical and technology companies, Mr. Wells has also worked in the water treatment, supply-chain management, manufacturing and professional services industries.

He has led multiple public offerings, reverse mergers, private placements, and M&A transactions. He has completed a deSPAC transaction (Envoy Medical, NASDAQ: COCH), Initial Public Offering (ENDRA Life Sciences Inc. NASDAQ: NDRA), and multiple reverse mergers.

Mr. Wells joined the Board of Directors of Heart Test Laboratories, Inc. (dba ‘HeartSciences’, NASDAQ: HSCS), which is developing a cardiac device which seeks to bridge today’s “diagnostic gap” in cardiac care by providing effective front-line solutions that assist in the detection of heart disease in at-risk patients. He holds an MBA from Pepperdine University, and his Bachelors degree is from Seattle Pacific University majoring in Finance and Entrepreneurship.